顏婉菁

DSCF1132-Final-1顏婉菁  研究員
生技與藥物研究所
Email: jeanwcyen@nhri.edu.tw

 

EDUCATION

  • 1989-1993 University of Southern California, School of Pharmacy (Ph. D.,Pharmaceutics).
  • 1985-1988 University of California, Davis (B.S., Biochemistry).

RESEARCH INTERESTS

Translational cancer research, oncology drug discovery; experimental therapeutics, cancer pharmacology, drug resistance and metastasis

RESEARCH ACTIVITIES AND ACCOMPLISHMENTS

Dr. Yen has 15+ years academia and industry experiences focused on oncology drug research with an emphasis in in vivo cancer biology, biomarker discovery and translational cancer research. She has strong understanding of pre-clinical drug discovery and development and working knowledge of oncology disease processes, disease models and current clinical treatments. Her ability to use strong science to drive strategic direction was demonstrated by bringing several research stage oncology drug discovery programs into early clinical development and effectively connect preclinical research findings with clinical strategy. She has track records of publications in prestigious journals and is co-inventors for several patents.

PROFESSIONAL EXPERIENCES

  • 2017 – present – Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan
  • 2016 – Consultant, OncoMed Pharmaceuticals, Inc.
  • 2013-2015 – Sr. Scientist II/Group Lead, OncoMed Pharmaceuticals, Inc.
  • 2008-2013 – Sr. Scientist, OncoMed Pharmaceuticals, Inc.
  • 2006-2008 – Scientist, OncoMed Pharmaceuticals, Inc.
  • 2000-2005- Research scientist, Ligand Pharmaceuticals, Inc.
  • 1998-2000 – Research scientist, College of Pharmacy, The Ohio State University
  • 1995-1998 – Research associate, College of Pharmacy, The Ohio State University
  • 1993-1995 – Postdoctoral fellow, College of Pharmacy, The Ohio State University.
  • 1989-1993 -Research assistant, Department of Pharmaceutical Sciences, University of Southern California.

PROFESSIONAL SERVICES

  • 2007-2011 – Member, The Institutional Animal Care and Use Committee, OncoMed Pharmaceuticals, Inc.
  • 1993-2000 – Journal reviewer, Pharmaceutical Research/Journal of Drug Targeting

SELECTED PUBLICATIONS

  1. Lai YL, Wang KH, Hsieh HP, Yen WC*. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma. J Biomed Sci. Under revision. *: Corresponding author.
  2. Lee KH, Yen WC, Lin WH, Wang PC, Lai YL, Su YC, Chang CY, Wu CS, Huang YC, Yang CM, Chou LH, Yeh TK, Chen CT, Shi C, Hsieh HP. Discovery of BPR1R024, an orally active and selective CSF1R inhibitor that exhibits antitumor and immunomodulatory activity in a murine colon tumor model. J Med Chem. 2021;64:14477-14497.
  3. Fischer MM, Yeung V, Cattaruzza F, Hussein R, Yen WC, Murriel C, Evans JW, O’Young G, Brunner AL, Wang M, Cain J, Cancilla B, Kapoun A, Hoey T. RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations. Sci Rep. 2017;7:15270.
  4. Fischer, MM, Cancilla B, Yeung V, Cattaruzza F, Chartier C, Murriel CL, Cain J, Tam R, Cheng C-Y, Evans JW, O’Young G, Song X. Lewicki J, Kapoun AM, Gurney A, Yen WC, Hoey T. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv. 2017;3:e1700090.
  5. Chartier C, Raval J, Axelrod F, Bond C, Cain J, Dee-Hoskins C, Ma S, Fischer MM, Shah J, Wei J, Lam A, Stroud M, Yen WC, Yeung P, Cancilla B, O’Young G, Wang M, Kapoun AM, Lewicki J, Hoey T, Gurney A. Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types. Cancer Res.2016;76:713-723.
  6. Yen WC*, Fischer MM, Axelrod F, Bond C, Cain C, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Lewicki J, Gurney A, Hoey T. Targeting Notch signaling by a dual Notch2/3 antibody (tarextumab) inhibits tumor growth and decreases cancer stem cell frequency in solid tumors. Clin Cancer Res. 2015;21:2084-2095. *: Corresponding author.
  7.  Yen WC*, Fischer M, Hynes M, Wu J, Kim E, Beviglia L, Yeung P, Kapoun AM, Lewicki J, Gurney A, Simeone DM, Hoey T. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin Cancer Res. 2012;19:5374-5386.  *: Corresponding author.
  8. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, M S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T. Wntpathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA. 2012;19:11717-11722.
  9. &Fischer M, & Yen WC, Kapoun AM, Wang M, O’Yang G, Lewicki J, Gurney A, Hoey T. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 2011;71:1520-1525. &: Equal contributions.
  10. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Park IK, Sato A, Satyal S, Lewicki J, Gurney A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009;5:168-177.
  11. Lopez FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, Leibowitz M., Marschke K, Rosen J, Rungta D, Viveros H, Yen WC, Zhi L, Negro-Vilar A, Miner, JN. LGD5552, an anti-inflammatory glucocorticoid receptor ligand with reduced side effects in vivo.  Endocrinology. 2008;149:2080-2089.
  12. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) reverses gemcitabine resistance associated genes in gemcitabine-resistant non-small-cell lung cancer. Cancer Res. 2007;67:4425-4433.
  13. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW: The combination of a retinoid X receptor agonist bexarotene (LGD1069, Targretin) and a peroxisome proliferators activator receptor agonist rosiglitazone act together to inhibit growth and induce differentiation in colon cancer. Cancer Lett. 2006;240:225-233.
  14. Yen WC*, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) inhibits angiogenesis and metastasis in solid tumors. Br J Cancer. 2006;94:654-660. *: Corresponding author.
  15. Yen WC*, Lamph W W. A selective retinoid X receptor agonist bexarotene prevents and overcomes multidrug resistance in advanced prostate cancer. The Prostate. 2006;66:305-316.
    *: Corresponding author.
  16. & Hermann TW, & Yen WC, Tooker P, Fan BQ, Roegner K, Negro-Vilar A, Lamph WW Bissonnette RP. The retinoid X receptor (RXR) agonist bexarotene (LGD1069, Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small-cell lung cancer (NSCLC) cell lines. Lung Cancer. 2005;50:9-18. &: Equal contributions.
  17. Yen WC, Lamph WW. A selective retinoid X receptor agonist bexarotene prevents and overcomes acquired drug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005;4: 824-834.
  18. Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW. A selective retinoid X receptor agonist LGD1069 (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer (NSCLC). Clin Cancer Res. 2004;10:8656-8664.
  19. Yen WC, Prudente RY, Lamph WW. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat. 2004;88:141-148.
  20. Yen WC, Au JL-S. Pharmacodynamic evaluation of mitomycin C analog BMS 181174 for intravesical bladder cancer chemotherapy. Pharm Res. 1997;14:241-245.
  21. Yen WC, Schmittgen T, Au J L.-S. Different pH-dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm Res. 1996;13:1887-1891.
  22.  Yen WC, Wientjes GM, Au JL.-S. Differential effect of Taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm Res. 1996;13:1296-1303.
  23. Yen WC and Lee VHL. Paracellular transport of a proteolytically labile
    pentapeptide across the colonic and other intestinal segments of the albino rabbit: Implications for peptide drug design.  J Contr Rel. 1994;28:97-109.

PATENTS

  1. Chen CH, Yen WC, Yeh TK, Chen CT, Wang HJ, Huang KF. Methods of increasing cell phagocytosis. US provisional patent number 63,245,540. Priority Date: 9/17/2021.
  2. Lewicki A, Gurney A, Hoey T, , Yen WC, Satyal S. Antibodies to a non-ligand binding region of at least two Notch receptors. US patent number 9,676,865. Grant Date: 6/13/2017
  3. Lewicki A, Gurney A, Hoey T, , Yen WC, Satyal S. Methods of treating cancer using antibodies to a non-ligand binding region of Notch1. US patent number 8,784,811. Grant Date: 7/22/2014
  4. Lewicki A, Gurney A, Hoey T, Yen WC, Satyal S. Antibodies to the Notch1 receptor. US patent number 8,404,237. Grant Date: 3/26/2013
  5. Lewicki A, Gurney A, Hoey T, Yen WC, Satyal S. Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2. US patent number 8,206,713. Grant Date: 6/26/2012
  6. Lewicki A, Gurney A, Hoey T, Yen WC, Satyal S. Antibodies to Notch receptors. US patent number 7,919,092. Grant Date: 4/5/2011
  7. Lee VHL, Yen WC. Methods and compositions for epithelial drug transport. US patent number 5,534,496. Grant Date: 7/9/1996

AWARDS

  • 2005- Outstanding Achievement Award, Ligand Pharmaceuticals, Inc.
  • 1993- Graduate Student Scientific Poster Award in Targeted Delivery to the Gastrointestinal Tract, Capsugel Worldwide Symposium.
  • 1993- Pharmaceutical Manufacturers Association (PMA) Advanced Predoctoral Fellowship.
  • 1992- AAPS Graduate Symposium Award in Drug Delivery and Pharmaceutical Technology.

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

  • 1990-2003       Member, American Association of Pharmaceutical Sciences
  • 1993-1997        Member, Controlled Release Society
  • 1993-1998        Associated member, American Association for Cancer Research
  • 1999-present   Member, American Association for Cancer Research

Comments are closed.